Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer

Biological Procedures Online

Review

Shiguo/SG Zhu¹  Shulin/SL Li²  Jun/J Shi³  Yabin/YB Gong³  Yan Lu³  Ling/ L Xu³ 

[1] Department of Immunology and Pathogenic Biology, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, 1200 Cai Lun Rd, Shanghai, China;MD Anderson Cancer Center, the university of Texas, 1840 Old Spanish Trail, Houston, TX, USA;No.2 oncology department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, No.110, Ganhe Rd, Shanghai, China;

关键词: Lung cancer;    Liquid biopsy;    ctDNA;    Circulating RNA;    Methylation;   

DOI  :  10.1186/s12575-017-0051-8

 received in 2017-02-04, accepted in 2017-03-02,  发布年份 2017

来源: Springer

【 摘 要 】

DNA/RNA methylation plays an important role in lung cancer initiation and progression. Liquid biopsy makes use of cells, nucleotides and proteins released from tumor cells into body fluids to help with cancer diagnosis and prognosis. Methylation of circulating tumor DNA (ctDNA) has gained increasing attention as biomarkers for lung cancer. Here we briefly introduce the biological basis and detection method of ctDNA methylation, and review various applications of methylated DNA in body fluids in lung cancer screening, diagnosis, prognosis, monitoring and treatment prediction. We also discuss the emerging role of RNA methylation as biomarkers for cancer.

【 授权许可】

CC BY   
© The Author(s). 2017